Table of Contents
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant toRule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Commission FileNumber: 001-38757
For the month of January 2019
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho2-Chome
Chuo-ku,Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under coverForm 20-F orForm 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(7): ☐
Table of Contents
Information furnished on this form:
Exhibit | ||
1. | Notice regarding the Court Sanction with respect to the Acquisition of Shire plc. by Takeda Pharmaceutical Company Limited |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||
Date: January 4, 2019 | By: | /s/ Mitsuhiro Okada | ||||
Mitsuhiro Okada | ||||||
Head of Global Treasury & Finance Management |
Table of Contents
![]() | Better Health, Brighter Future |
News Release
Notice regarding the Court Sanction with respect to
the Acquisition of Shire plc. by Takeda Pharmaceutical Company Limited
Osaka, Japan, January 4, 2019 - In relation to the proposed acquisition (the “Acquisition”) of Shire plc by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), as announced in the “Agreement on Commencement of a Friendly Acquisition Procedure to Make Shire plc a Wholly-owned Subsidiary” on May 8, 2018, Takeda confirms that the Royal Court of Jersey has on January 3, 2019 (GMT) sanctioned the scheme of arrangement (the “Scheme”) pursuant to which the Acquisition is being implemented.
It is expected that the offering terms for the issuance of the new Takeda shares as part of the consideration for the Acquisition will be determined on January 5, 2019 (JST) and that the effective date of the Scheme will be January 8, 2019 (JST).
###